Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | proteasome (prosome, macropain) subunit, beta type, 5 | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | proteasome subunit alpha type-5, putative | proteasome (prosome, macropain) subunit, beta type, 5 | 160 aa | 148 aa | 23.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0086 | 0.5 | 0.5 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0086 | 0.5 | 0.5 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0086 | 0.5 | 0.5 |
Echinococcus granulosus | proteasome prosome macropain | 0.0086 | 0.5 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0086 | 0.5 | 0.5 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0086 | 0.5 | 0.5 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0086 | 0.5 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0086 | 0.5 | 0.5 |
Mycobacterium ulcerans | proteasome PrcB | 0.0086 | 0.5 | 0.5 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0086 | 0.5 | 0.5 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0086 | 0.5 | 0.5 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0086 | 0.5 | 0.5 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0086 | 0.5 | 0.5 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0086 | 0.5 | 0.5 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0086 | 0.5 | 0.5 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0086 | 0.5 | 0.5 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0086 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 9.88 uM | Inhibition of chymotrypsin-like activity of 20S human proteasome assessed as Suc-LLVY-AMC hydrolysis at using Promega proteasome-Glo-3 substrate incubated for 15 mins by luminescence assay | ChEMBL. | 27158142 |
IC50 (binding) | = 102.7 uM | Inhibition of caspase-like activity of 20S human proteasome assessed as Z-nLPnLD-AMC hydrolysis at using Promega proteasome-Glo-3 substrate incubated for 15 mins by luminescence assay | ChEMBL. | 27158142 |
IC50 (binding) | = 220.1 uM | Inhibition of trypsin-like activity of 20S human proteasome assessed as Z-LRR-AMC hydrolysis at using Promega proteasome-Glo-3 substrate incubated for 15 mins by luminescence assay | ChEMBL. | 27158142 |
Inhibition (binding) | = 99.5 % | Inhibition of chymotrypsin-like activity of 20S human proteasome assessed as Suc-LLVY-AMC hydrolysis at 25 ug/ml using Promega proteasome-Glo-3 substrate incubated for 15 mins by luminescence assay | ChEMBL. | 27158142 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.